Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Payables (2023 - 2026)

Contineum Therapeutics' Payables history spans 4 years, with the latest figure at $1.5 million for Q1 2026.

  • Quarterly Payables fell 58.98% to $1.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Mar 2026, down 58.98% year-over-year, with the annual reading at $1.0 million for FY2025, 43.9% down from the prior year.
  • Payables came in at $1.5 million for Q1 2026, up from $1.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.6 million in Q1 2025 to a low of $570000.0 in Q1 2024.
  • The 4-year median for Payables is $1.2 million (2024), against an average of $1.4 million.
  • Year-over-year, Payables skyrocketed 539.47% in 2025 and then tumbled 58.98% in 2026.
  • Contineum Therapeutics' Payables stood at $635000.0 in 2023, then soared by 185.2% to $1.8 million in 2024, then crashed by 43.9% to $1.0 million in 2025, then surged by 47.15% to $1.5 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Payables are $1.5 million (Q1 2026), $1.0 million (Q4 2025), and $786000.0 (Q3 2025).